STAT

Opinion: What using animals for scientific research taught me about myself

When I looked for the deeper meaning of existence, I found that I was too skeptical for heaven and hell, for deities and spirits. Sometimes, I thought about astrophysics — roiling energy, dark matter, the multiple dimensions of an expanding universe — but it was all too vast and distant. The closest I ever got to a mystical experience was working with animals as a molecular biologist.

As a biologist, I performed experiments on flatworms, sea urchins, zebrafish, frogs, opossums, and mice. These studies required the careful administration of life and death: I merged sperm with eggs and observed early embryos when they were just three layers of tissues flattened together. At certain times, I preserved animals in formaldehyde and bathed them in chemicals that turned their bodies transparent.

In the lab, life and death were demythologized. Instead of some immense, cosmic force, they shrank into something tangible that could be contained in a Petri dish or studied under a microscope.

Read more: Coming to terms with six years in science: obsession, isolation, and moments of wonder

Watching generations of animals flash in and out of existence, I also felt time compressing. I cared for zebrafish embryos that, in a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks